For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- MHLW to Examine Bayer Issue from Pharmaceutical Law Viewpoint without Prejudgment: Bureau Chief
April 21, 2017
- Lawmakers Whispering Thresholds for Off-Year-Revision Products; Top 30% in Discrepancy Rates Floated
April 21, 2017
- MOF Puts June-End Generic Share at Around 65%, Just Shy of Mid-Year 70% Target
April 21, 2017
- MOF Calls for Scrapping Price Maintenance Premium
April 21, 2017
- MHLW Cautions on Incidences of Multiple Vertebral Body Fractures after Discontinuation of Pralia Treatment
April 21, 2017
- MHLW Re-Cautions Use of Sleep/Anxiolytic/Epilepsy Agents Containing 44 APIs
April 19, 2017
- Optimal Use Guidelines Issued for Opdivo Use in RCC, Hodgkin’s Lymphoma
April 19, 2017
- New MHLW Panel Starts Discussions on Proper Drug Use Guidelines for Elderly; Final Report Expected by End of FY2018
April 19, 2017
- Amicus Takes Over GSK’s Orphan Status for Migalastat for Fabry’s Disease
April 18, 2017
- Review of 14-Day Prescription Limit Up for Chuikyo Discussion Again
April 18, 2017
- AMED to Launch Portal Site to Promote Use of Biobanks as Part of Effort to Support Genomic Medicine
April 18, 2017
- With Clinical Research Law Enacted, MHLW Eyes New Panel to Discuss Requirements for “Specified Clinical Research”: R&D Division Head
April 17, 2017
- Japan, South Korea to Hold 2nd Joint Regulation Symposium in May
April 17, 2017
- Clinical Research Law Promulgated
April 17, 2017
- MHLW Never Pressured Bayer on Announcement Timing for Xarelto Issue: Official
April 14, 2017
- Tokyo Govt Orders 2 “Cash-and-Carry” Dealers to Suspend Business
April 14, 2017
- Pricing Debate Timeline Updated, with 3 Hearing Sessions Now Planned
April 13, 2017
- CEFP Setting Sights on Drug Pricing, High-Cost Benefit System
April 13, 2017
- Opdivo’s Optimal Use Guidelines for RCC, Hodgkin’s Lymphoma to Take Effect on April 18
April 13, 2017
- Scrutinize Specific Process of Cost-Based Drug Pricing: Chuikyo Subcommittee
April 13, 2017
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…